One of the most disturbing aspects of the COVID-19 pandemic is the strange singularity of the ultimate solution, or at least the one preferred by the world’s most powerful people and their media: vaccines.
The civil rights organisation AfriForum & Dr George Coetzee today achieved a further success in the fight for access to ivermectin including off-label use.
Our investigation of a large national cohort appears to support early administration (within the first 3 to 7 days of COVID-19 diagnosis) of HCQ in mild COVID-19 disease in an outpatient setting for reducing hospitalizations and deaths without any serious adverse HCQ-related effects.
If this finding is confirmed in future clinical trials, HCQ as a cheap and available drug may still play a role in a specific population with respect to reducing COVID-19 burden, particularly in resource-poor countries.
